Results

Total Results: 2,080 records

Showing results for "drug".

1581. Data Points 14: Use of Endocrine Therapy (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/dcis-endocrine-therapy_research.pdf
      August 01, 2012 - therapy use over a five-year period for newly diagnosed women, because event data from the Medicare drug

1582. Assessing the Impact of Indexing Performance Measure Codes on the Perceived Value of EPC Reports to Health Systems (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-assessing-impact.pdf
      September 01, 2018 - target high-modifiable medication risk patients including home-visitations, telephonic and e-consults drug

1583. Dispostion of Comments Report for Child and Adolescent Exposure to Trauma (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/trauma-child-interventions_disposition-comments.pdf
      February 11, 2013 - Dispostion of Comments Report for Child and Adolescent Exposure to Trauma Source: http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and- reports/?pageaction=displayproduct&productID=1383 Published Online: February 11, 2013 Comparative Effectiveness Research Review Disposition of Comments Report …

1584. Evidence Summary: Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-221-copd-evidence-summary_0.pdf
      October 01, 2019 - Current drug treatment, chronic and acute. Clin Chest Med. 2014 Mar;35(1):177-89.

1585. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/autism-adolescents_research-protocol.pdf
      March 29, 2011 - Food and Drug Administration (FDA)-approved medications for the treatment of irritability in ASD: risperidone … language, skills, or behaviors - Increases in or worsening of comorbid symptoms - Adverse reactions to drug

1586. Treatment of Dementia Among Community-Dwelling and Institutionalized Medicare Beneficiaries | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/dementia-databases-methods/research
      May 22, 2008 - Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD. 2 Peter Lamy Center on Drug … settings was also found despite the different method of measuring medication use, with institutional drug … This relationship also held in the community, albeit overall rates of drug use were lower (15.5% versus … particularly important to replicate this work given that new drugs (specifically memantine) and other drug … The quality of antipsychotic drug prescribing in nursing homes.

1587. Topic Brief: Supplemental Oxygen Prescribing Practices (pdf file)
      effectivehealthcare.ahrq.gov/system/files/docs/topic-brief-supplemental-oxygen.pdf
      October 16, 2020 - Does the nomination represent a health care drug, intervention, device, technology, or health care

1588. Comparative Effectiveness of Adjunctive Devices to Remove Thrombi or Protect Against Distal Embolization in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention of Native Vessels | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/acs-pci-adjunctive-devices/research-protocol
      July 01, 2010 - distal protection versus conventional treatment in primary percutaneous coronary intervention: the Drug

1589. Disposition of Comment Report for Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/wireless-motility-capsule_disposition-comments.pdf
      May 20, 2013 - Cisapride had benefit in prokinetic activity, but drug interactions limited its value. and so on... … It is physicians rather than patients who decide about using prokinetics or any other drug.

1590. Chronic-Urinary-Retention Research (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-urinary-retention_research.pdf
      September 01, 2014 - Patients with acute or transient retention attributed to drug side effects, medical or surgical procedures … Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment … /prostaglandin E2; CI = confidence interval; NR = not reported; RR=risk ratio * Uterine leiomyoma, drug … Reductase Inhibition Combined with an Alpha Blocker Urinary Retention|Benign Prostatic Hyperplasia Drug

1591. A Systematic Review of Postpartum Home Blood Pressure Monitoring, Postpartum Treatment of Hypertensive Disorders of Pregnancy, and Peripartum Magnesium Sulfate Regimens for Preeclampsia With Severe Features (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/hypertensive-disorders-pregnancy-protocol-amendment.pdf
      April 20, 2022 - Other clinically important adverse events* (e.g., hypotension, neuromuscular blockade) o Adverse drug … health disparities • Magnesium related toxicity • Other clinically important adverse events • Adverse drug

1592. Health Information Exchange (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/health-information-exchange_executive.pdf
      December 01, 2015 - Am Health Drug Benefits. 2011;4(4):207-15. PMID: 25126351. 6. … Am Health Drug Benefits. 2012;5(6):333-40. PMID: 24991331. 20.

1593. Diagnosis and Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-fatigue_executive.pdf
      July 01, 2016 - Food and Drug Administration (FDA) for the treatment of ME/CFS, but several have been used “off label … A controlled clinical trial with a specifically configured RNA drug, poly(I) midline dot poly(C12U)

1594. Psoriasis-Chronic Executive (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_executive.pdf
      November 01, 2012 - etanercept, and adalimumab), and one anti-IL 12/23 agent (ustekinumab) have approval from the Food and Drug … agents concluded a difference in efficacy, suggesting heterogeneity within the class and indicating drug … and therefore do not make between-class comparisons, rather limit comparisons with the individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug

1595. Comparative Effectiveness of Second Generation Antidepressants in the Pharmacologic Treatment of Adult Depression – An Update to a 2007 Report | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/antidepressants-update/research-protocol
      July 13, 2011 - relapse (i.e., continuation phase) or recurrence (i.e., maintenance phase) when a patient continues the drug … medications with new formulations (such as an extended release formulation) are approved by the Food and Drug … Administration (FDA) through an application called a supplemental new drug application (sNDA). … of interest is whether response or remission can be maintained if patients who have responded to one drug … If fewer than three head-to-head trials are available for any drug comparison, we will compute indirect

1596. Evidence Report on the (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/antidepressants-update_research-protocol.pdf
      July 13, 2011 - , continuation phase) or recurrence (i.e., maintenance phase) when a patient 1) continues the drug … medications with new formulations (such as an extended release formulation) are approved by the Food and Drug … Administration (FDA) through an application called a supplemental new drug application (sNDA). … interest is whether response or remission can be maintained if patients who have responded to one drug … If fewer than three head-to-head trials are available for any drug comparison, we will compute indirect

1597. #06 Developmental Delays ADHD, and Autism (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1506.pdf
      December 01, 2015 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … study examining metadoxine for treating adult ADHD; a similar trial is also planned to study this drug

1598. PREGNANCY, INCLUDING PRETERM BIRTH #12 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pregnancy-horizon-scan-high-impact-1412.pdf
      December 01, 2014 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … spontaneous preterm birth; interventions intended to target both the pregnant woman and fetus (a drug

1599. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/cognitive-decline/research-2017
      March 24, 2017 - Many interventions (e.g., nutraceuticals; one multimodal intervention using lifestyle advice and drug

1600. #14 SUBSTANCE ABUSE (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1512.pdf
      December 01, 2015 - Recent marketing data collected by the FDA’s Center for Drug Evaluation and Research indicates that … The drug potentially holds additional promise as an AUD therapy because its safety profile is better … Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions, and costs. … Mobile medical applications: guidance for industry and Food and Drug Administration staff. … Food and Drug Administration (FDA); 2015 Feb 9. 44 p.